Literature DB >> 6375361

Hemodynamic and regional blood flow response to captopril in congestive heart failure.

T B Levine, M T Olivari, J N Cohn.   

Abstract

In 19 patients with moderate to severe congestive heart failure the over-all hemodynamic response to captopril was compared with its effect on regional blood flow. Ninety minutes after administering a single dose of captopril (25 to 150 mg), right atrial pressure decreased from 6.1 +/- 6.1 to 3.2 +/- 5.1 mm Hg (p less than 0.001), pulmonary artery pressure from 33.1 +/- 8.3 to 26.5 +/- 9.1 mm Hg (p less than 0.001), pulmonary capillary wedge pressure from 22.4 +/- 6.2 to 15.2 +/- 7.4 mm Hg to (p less than 0.001), mean arterial pressure from 77.2 +/- 8.0 to 66.5 +/- 13.7 mm Hg (p less than 0.001), and systemic vascular resistance from 1,630 +/- 503 to 1,233 +/- 443 dyne-s-cm-5 (p less than 0.001), and cardiac index increased from 2.0 +/- 0.6 to 2.4 +/- 0.7 l/minute/m2 (p less than 0.001). Despite the significant increase in cardiac index there was no increase in either hepatic blood flow (203 +/- 212 to 142 +/- 101 units, N.S.) or forearm blood flow (2.2 +/- 0.9 to 2.2 +/- 1.0 ml/100 g per minute, N.S.) after captopril. Similarly, the global reduction in systemic vascular resistance was not accompanied by a reduction in either hepatic vascular resistance (0.93 +/- 0.90 to 0.83 +/- 0.69 units, N.S.) or forearm vascular resistance (41.3 +/- 18.4 to 34.9 +/- 12.4 mm Hg/ml/100 g per minute, N.S.). The over-all improvement in hemodynamics that is seen when captopril is given to patients with severe heart failure does not apply uniformally to all vascular beds. The heterogeneous response reflects the variable vasoconstrictor part played by the renin-angiotensin system in regulating flow to individual regional circulations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375361     DOI: 10.1016/0002-9343(84)90881-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Short term haemodynamic effects of converting enzyme inhibition before and after eating in patients with moderate heart failure caused by dilated cardiomyopathy: a double blind study.

Authors:  B Herrlin; C Sylvén; O Nyquist; O Edhag
Journal:  Br Heart J       Date:  1990-01

3.  Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.

Authors:  Xin Zhao; David Ho; Patricio Abarzúa; Sunil K Dhar; Xi Wang; Zhiheng Jia; Malar Pannirselvam; David J Morgans; Fady I Malik; Stephen F Vatner
Journal:  J Pharmacol Exp Ther       Date:  2011-07-22       Impact factor: 4.030

4.  Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.

Authors:  S Gasic; G Heinz; C Kleinbloesem; A Korn
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 5.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

Review 6.  ACE inhibitors in pediatric patients with heart failure.

Authors:  Kazuo Momma
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats.

Authors:  J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution.

Authors:  G Binetti; I Rubino; E Varani; R Spadoni; R M Ferretti; V Cervi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.